Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and strategy stratification are lacking. In this setting, a simple biological scoring system have recently been proposed, including LDH and CD138 binary status seric values, identifying one third of patients with worst prognostic. Intensified-chemotherapy strategies, combining 5-fluorouracile, Oxaliplatin, …

folfiri regimen
capecitabine
folfoxiri
adenocarcinoma
folfox regimen
  • 6 views
  • 03 Aug, 2021
  • 13 locations
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

  • 0 views
  • 08 Mar, 2021
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

bendamustine
tumor burden
neutrophil count
rituximab
lenalidomide
  • 37 views
  • 06 Sep, 2021
  • 37 locations
Proof of Concept Study of ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) monotherapy in patients with PNH that are treatment nave, or patients currently treated with eculizumab who still experience anemia and reticulocytosis, or patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent, …

anemia
complement inhibitor
eculizumab
ravulizumab
paroxysmal nocturnal hemoglobinuria
  • 2 views
  • 31 May, 2021
  • 9 locations
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by neoadjuvant systemic therapy. However, the optimal neoadjuvant induction regimen has not been defined, and no consensus exist on criteria for resectability. In this study colorectal cancer patients with initially unresectable liver-only metastases, as prospectively …

folfiri regimen
ct scan
panitumumab
folfox regimen
bevacizumab
  • 177 views
  • 23 Sep, 2021
  • 64 locations
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions. The role of radiation in NHL-DLBCL has been addressed in large cooperative trials showing improvement …

chop regimen
diffuse large b-cell lymphoma
hodgkin's disease
b-cell lymphoma
cancer
  • 83 views
  • 21 Jan, 2021
  • 1 location
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (LDH).

measurable disease
serum ldh
advanced melanoma
interferon
metastasis
  • 6 views
  • 08 Nov, 2020
  • 1 location
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

This is a pilot study evaluating the feasibility of using adaptive intermittent dosing of vemurafenib and cobimetinib in BRAF mutant patients with elevated baseline lactate dehydrogenase (LDH

measurable disease
mek inhibitor
unresectable melanoma
serum ldh
cobimetinib
  • 9 views
  • 19 Sep, 2021
  • 1 location
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

-risk cohorts including symptomatic brain metastases or liver metastases with elevated lactate dehydrogenase (LDH) or bulky systemic disease burden.

braf inhibitor
tumor cells
cytotoxic t-lymphocyte antigen 4
ipilimumab
brain metastases
  • 0 views
  • 22 Jul, 2021
  • 1 location
Effects of Phosphatidic Acid on Strength and Hypertrophy

, body composition, muscle cross-sectional area and food consumption. Samples of venous blood will also be collected to determine the concentration of creatine kinase (CK), lactate dehydrogenase (LDH

phosphatidic acid
strength training
igf-1
lactate dehydrogenase
insulin
  • 0 views
  • 25 Jan, 2021
  • 1 location